Fortrea Q1 2026: Revenue Drops, EBITDA Soars

Fortreas Q1 2026 earnings showcased resilience with a 2.3% revenue dip, yet adjusted EBITDA surged by 50%. Book-to-bill ratio stood at 1.15 and 1.05 for the quarter and trailing twelve months, respectively. The company launched FIT, an AI suite, and saw biotech wins, especially in oncology and RNA therapies. Sales in clinical pharmacology reached record highs. Net Promoter Scores improved due to enhanced site activations and quality leadership. Cost savings amounted to $16 million gross and $9 million net. Guidance for full-year revenue is $2.55-2.65 billion, adjusted EBITDA $190-220 million. The company aims for growth and mid-teens margins, leveraging AI and steadier demand. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/49d6c6a8dc1150b0